2024
Factors that impact aromatase inhibitor adherence in early-stage hormone receptor positive breast cancer.
Yang A, Baldwin E, Casasanta N, Tiersten A, Kier M. Factors that impact aromatase inhibitor adherence in early-stage hormone receptor positive breast cancer. Journal Of Clinical Oncology 2024, 42: e12524-e12524. DOI: 10.1200/jco.2024.42.16_suppl.e12524.Peer-Reviewed Original ResearchFirst-line AITherapy useSide effectsRecurrence riskBreast cancerNo significant differenceAromatase inhibitorsEarly-stage hormone receptor-positive breast cancerHormone receptor-positive breast cancerEfficacy of aromatase inhibitorsTreatment due to side effectsReceptor-positive breast cancerAI adherenceEarly-stage breast cancerSocioeconomic demographicsPatients' recurrence riskCohort median agePositive breast cancerSignificant differenceFisher's exact testSide effect frequencyPearson chi-square testKruskal-Wallis rank sum testRank sum testEndocrine treatment
2022
Socioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer.
Kier M, Li Z, Casasanta N, Patel R, Agarwal P, Zimmerman B, Yang Y, Fink M, Zhou X, Newman S, Chen R, Schadt E, Oh W, Tiersten A. Socioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer. Journal Of Clinical Oncology 2022, 40: 523-523. DOI: 10.1200/jco.2022.40.16_suppl.523.Peer-Reviewed Original ResearchRate of discontinuationSupportive therapyBreast cancerAI therapyDiscontinuation ratesSocioeconomic disparitiesInsurance coverageEarly-stage hormone receptor-positive breast cancerSide effectsExact testHormone receptor-positive breast cancerAdjuvant aromatase inhibitor therapyReceptor-positive breast cancerHormone-positive breast cancerInitial AI therapyAromatase inhibitor therapyRetrospective chart reviewMajority of patientsPositive breast cancerBreast cancer survivalFisher's exact testLow socioeconomic statusAdjuvant AIPrimary languageEarly discontinuation
2019
Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score
Casasanta N, Kipnis S, Linville L, Lipinski S, Knoedler A, Marino A, McHenry A, Biagi T, Stark E, Amdur R, Denduluri N, Rodriguez P, Isaacs C, Kaltman R. Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score. Clinical Breast Cancer 2019, 20: 125-130. PMID: 31526714, DOI: 10.1016/j.clbc.2019.07.004.Peer-Reviewed Original ResearchConceptsGermline mutation statusOncotype DX recurrence scoreBreast cancer patientsRecurrence scoreMutation statusOncotype DXAssociation of RSGermline mutationsCancer patientsHormone receptor-positive breast cancer patientsHereditary cancer riskGermline genetic testingGenetic risk assessmentHereditary cancer syndromesAssociated with germline mutationsBenefit of chemotherapyRetrospective analysis of dataMultivariate logistic regression modelLikelihood of recurrenceFisher's exact testMultivariate logistic regressionCounseling of family membersLogistic regression modelsNon-BRCA1/2BRCA2 genes